Hengrui Pharma's Innovation Strategy Fuels Record Growth and Global Push

SHANGHAI – April 22, 2026 – Hengrui Pharma today showcased the potent results of its long-term strategic pivot, reporting robust first-quarter growth that significantly outpaces the broader pharmaceutical market. The Chinese pharmaceutical giant's impressive financial performance, with revenue climbing 12.98% to RMB 8.14 billion and net profit surging 21.78% to RMB 2.28 billion, is directly fueled by a dual-engine strategy: a relentless focus on in-house innovation and an increasingly sophisticated approach to global expansion.

The Q1 2026 results underscore a clear trend. Hengrui is no longer just a major player in China; it is successfully transforming into a globally competitive, innovation-driven powerhouse. The company's success provides a compelling blueprint for how established pharmaceutical firms can reinvent themselves to thrive in a new era of medicine.

The Roaring Engine of R&D

At the heart of Hengrui's success is a deep and sustained commitment to research and development. In the first quarter alone, the company invested a staggering RMB 2.22 billion in R&D, representing over 27% of its revenue. This figure is not an anomaly but a continuation of a multi-year strategy, with R&D spend consistently hovering near 30% of sales, a rate that rivals or exceeds many global pharmaceutical leaders.

This massive investment is yielding tangible, market-moving results. Sales from innovative drugs, the direct output of this R&D engine, skyrocketed by 25.75% year-over-year to RMB 4.53 billion. These high-value therapies now account for nearly 62% of the company's total pharmaceutical sales, a dramatic increase from just under 50% in 2024. This shift demonstrates a successful transition away from a reliance on generics towards a more sustainable and profitable model built on proprietary science.

The pipeline's momentum is palpable. During the quarter, Hengrui secured three key approvals in China for new innovative products and indications, including a cutting-edge anti-PD-L1/TGF-βRII bi-functional fusion protein for oncology and an expanded use for a HER2-targeting antibody-drug conjugate (ADC). Looking forward, the pipeline remains packed with potential, with the company gaining 26 new clinical trial approvals and having eight new drug applications accepted for review in China across its core therapeutic areas of oncology, metabolic, cardiovascular, and immunological diseases. With over 100 proprietary products in clinical development, the company anticipates approximately 53 new product and indication approvals between 2026 and 2028, signaling a steady stream of future growth drivers.

A New Blueprint for Global Expansion

While its R&D engine powers drug discovery, Hengrui's business development team is executing a multi-pronged strategy to bring these innovations to the global stage. The company's globalization efforts have evolved far beyond simple exports, now encompassing sophisticated out-licensing deals, strategic alliances, and novel corporate structures.

Business development has become a significant and recurring revenue stream, contributing RMB 787 million in the first quarter, largely from a major collaboration with global pharma giant GSK. This partnership, one of 12 major overseas deals completed since 2023, highlights the increasing global recognition of Hengrui's innovative portfolio. These agreements not only provide non-dilutive capital but also validate the quality of Hengrui's science and provide pathways into heavily regulated Western markets.

Perhaps the most telling sign of Hengrui's global ambition is the success of its "NewCo" strategy. This innovative approach involves spinning off specific, high-potential assets into new, independent companies to accelerate their development and unlock their value. The prime example is Kailera Therapeutics (NASDAQ: KLRA), a company built around Hengrui's promising GLP-1 assets for metabolic diseases. Kailera's successful IPO on the Nasdaq in Q1 2026 marks a pivotal milestone. This move allows the GLP-1 portfolio to be advanced by a focused team with access to U.S. capital markets and expertise, while Hengrui retains significant upside as a major shareholder. This strategy serves as a potential blueprint for monetizing other assets in its deep pipeline, providing a repeatable model for growth and global integration.

Sustained Performance and Market Confidence

The strong Q1 2026 results are part of a larger narrative of sustained, high-level performance. The company's revenue and profit growth have consistently outstripped industry averages for several years. In 2025, revenue grew 13% and net profit by 21.8%, while 2024 saw an even more dramatic surge, with revenue up 22.6% and net profit soaring 47.3%. This consistent outperformance, especially when the global pharmaceutical market's growth is in the single digits, has captured the attention of investors and analysts.

The market has responded positively to this track record of execution. Analysts have maintained "Buy" ratings on the company's stock, with experts noting that Hengrui's transformation is improving its profit quality and opening significant growth opportunities in the international market. The successful execution of its innovation and globalization strategies provides a clear and compelling growth story.

As Hengrui continues to advance its pipeline of over 100 innovative candidates and leverage its unique NewCo and partnership models, it is solidifying its position not just as a leader in China, but as an emerging force in the global pharmaceutical landscape. The company's journey demonstrates a powerful synergy where intensive scientific research fuels commercial success, and savvy global strategy multiplies its impact, promising to bring more innovative therapies to patients worldwide.